BERNS PAUL L purchased $20.0M of KARD (indirect holdings)

BERNS PAUL L purchased 1,250,000 indirectly-held shares of Kardigan, Inc. (KARD) at $16.00 ($20.00M total) on 2026-06-22.

Original reporting
SEC EDGAR · BERNS PAUL L
Published Jun 24, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KARD
Bullish
medium confidence
Mentioned
$KARD
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KARDBullishLow
01

Why it matters

The newest fact is the $20M open-market purchase by a director/10% owner (indirect holdings) at a stated price of $16.00 per share.

02

Market read

Primarily a sentiment/positioning datapoint; without accompanying fundamental updates, it is unlikely to drive sustained repricing by itself.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still discount the signal if the purchase timing aligns with non-informational factors (e.g., tax/estate planning, prior commitments).

Relevance 8/10Novelty 6/10Timing: after-hours/filing update (Form 4 filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Kardigan, Inc. (KARD).

Company-level read

Ticker impact

$KARDBullishMedium confidence
Context

SEC Form 4 shows director/10% owner BERNS PAUL L bought 1,250,000 shares of KARD at $16.00 on 2026-06-22.

Expected impact

Near-term impact likely limited; any effect is sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and sizable ($20M), but it does not include guidance, contracts, or regulatory/financial datapoints that typically move the stock materially.

Market effects

No sector-level read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A large insider buy can be driven by liquidity planning or diversification of indirect holdings rather than a forward-looking view on fundamentals.

Key entities

  • Kardigan, Inc.

    Subject of the Form 4 insider transaction; director/10% owner reported an open-market purchase.

  • BERNS PAUL L

    Director and 10% owner who reported the purchase; holdings increased to 15,042,035 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KARDMedAI 8/10

Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollme

$KARDMedAI 8/10

Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results

Kardigan (NASDAQ:KARD) extends Phase 2 trial of ataciguat, targeting 2027 results. Study finds 27% of mild to moderate patients are fast progressors, with higher risks of valve repair and hospitalization. Cardiac dysfunction prevalent in 80% of patients. Baseline data shows valve calcium as an independent risk marker. Ataciguat's potential effects on valve and heart muscle remain under investigation.

$KARDMedAI 8/10

Kardigan completes enrollment in Phase 2b aortic stenosis trial

Kardigan Inc. (NASDAQ:KARD) completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, enrolling 156 participants. The protocol was amended to assess aortic valve calcium at Week 48. Baseline data showed varying levels of aortic valve calcium and related conditions. Topline data is expected in late 2027. The company also presented findings from a retrospective analysis of aortic stenosis progression.

$KARDMedAI 9/10

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of…

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Regulation FD Disclosure. PRESS RELEASE Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alo